Adrenochrome Monosemicarbazone is a hemostatic agent derived from the oxidation product of epinephrine (adrenaline). It acts as a capillary stabilizer and systemic hemostat, primarily used to control bleeding from small blood vessels by reducing capillary permeability and fragility. It is not a vasoconstrictor or coagulant. Its clinical use in modern Indian practice is limited and largely historical, having been superseded by more effective and targeted hemostatic agents.
Adult: 0.75mg to 1.5mg (1 to 2 tablets) orally, three times daily. Alternatively, 0.75mg (1ml) by intramuscular injection once or twice daily. Note: Dosage is based on outdated literature.
Note: Tablets: To be taken with or without food. Injection: For deep intramuscular injection only. Do not administer intravenously.
Adrenochrome Monosemicarbazone is believed to reduce capillary permeability and increase capillary resistance. It does not affect blood coagulation factors, platelet aggregation, or cause vasoconstriction. Its proposed mechanism involves strengthening the inter-endothelial cement in capillary walls, thereby reducing the tendency for diapedesis and hemorrhage from small vessels.
Pregnancy: Category C: Animal reproduction studies have not been conducted. It is not known whether it can cause fetal harm. Use only if clearly needed and potential benefit justifies potential risk. Not recommended.
Driving: May cause dizziness; patients should be cautioned about driving or operating machinery if affected.
| Anticoagulants (Warfarin, Acenocoumarol) | Theoretical antagonism of hemostatic effect. | Moderate |
| Antiplatelet drugs (Aspirin, Clopidogrel) | Theoretical antagonism of hemostatic effect. | Moderate |
Same composition (Adrenochrome Monosemicarbazone (0.75mg)), different brands: